Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support OAC consideration in CHADS2=1 patients; leaves open randomized confirmation of net benefit.
In this clinical trial, patients with a CHADS(2)=1 had a low risk of stroke, yet still derived a modest (<1% per year) but statistically significant absolute reduction in stroke with OAC and had low rates of major hemorrhage on OAC.
No takes yet. Share an insight, caveat, or question.
Healey et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: